For more information on Age-Related Macular Degeneration go to the NHS website. If you've had a diagnosis, in addition to ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

People who are of European descent may be more at risk of age-related macular degeneration than those of African or Hispanic ...

最近，来自意大利技术研究院和圣马蒂诺医院的研究人员发现了一种名为Ziapin2的分子，它像一个精确的“光开关”，可以在视网膜中恢复对光的正常反应。这项研究发表在2025年1月11日的Nature Communications期刊上，论文标题为“A ...

Our vision declines as we age leading to the development of various eye conditions such as presbyopia cataracts and glaucoma ...

Collaboration between TLI and AMDF underscores a shared commitment to making a meaningful difference in the lives of those affected by AMD. Together, TLI and AMDF are dedicated to advancing awareness, ...

Susvimo is also approved to treat age-related macular degeneration, and the medication, ranibizumab, is delivered though a ...

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat ...

INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the ...

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age‐related macular degeneration (wet AMD) and diabetic ...